Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02177461
Recruitment Status : Completed
First Posted : June 27, 2014
Last Update Posted : July 8, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to assess the efficacy and tolerability of Telmisartan 40-80 mg once daily compared with enalapril 10-20 mg once daily in elderly patients with arterial hypertension.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Telmisartan Drug: Enalapril Drug: Clonidine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 374 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A PROBE (Prospective, Randomised, Open-Label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80mg Once Daily Compared With 10-20 mg Enalapril Once Daily Over a Period of 24 Weeks in Elderly Patients With Blood Hypertension
Study Start Date : April 2000
Actual Primary Completion Date : August 2002

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Telmisartan Drug: Telmisartan
Active Comparator: Enalapril Drug: Enalapril
Experimental: Telmisartan + clonidine TTS1 Drug: Telmisartan
Drug: Clonidine
Active Comparator: Enalapril + clonidine TTS1 Drug: Enalapril
Drug: Clonidine



Primary Outcome Measures :
  1. Change from baseline in 24-hours mean systolic blood pressure (SBP) (ABPM - ambulatory blood pressure measurement, 24 hours mean represents the average of 24 hourly mean values) [ Time Frame: Baseline and week 8 ]

Secondary Outcome Measures :
  1. Comparison of SBP ABPM tracing profile [ Time Frame: Week 8 and 24 ]
  2. Changes from baseline in trough cuff (sphygmomanometer) SBP [ Time Frame: Baseline, week 8 and 24 ]
  3. Smoothness index in comparison with baseline [ Time Frame: Baseline, week 8 and 24 ]
  4. Number of responders [ Time Frame: Week 8 and 24 ]
  5. Number of controlled responders [ Time Frame: Week 8 and 24 ]
  6. Incidence of adverse events [ Time Frame: 24 weeks ]
  7. Number of patients who withdraw due to adverse events [ Time Frame: 24 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 65 years
  • Sitting systolic blood pressure (SBP) ≥ 160 mmHg and any diastolic blood pressure (DBP) (safety maximum of sitting DBP 110 mmHg), measured by manual cuff sphygmomanometer at the end of the wash-out period
  • Written informed consent

Exclusion Criteria:

  • Secondary hypertension
  • Malignant hypertension (retinal haemorrhage, exudates or papillary oedema)
  • Clinically significant sodium depletion as defined by serum sodium level < 130 mEq/L, clinically significant hyperkaliemia as defined by serum potassium level > 5.5 mEq/L, clinically significant hypokaliemia as defined by serum potassium level < 3.0 mEq/L
  • Atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which could interfere with the cardiac rhythm
  • Heart rate < 50 bpm
  • Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF III-IV)
  • Angina pectoris or myocardial infarction
  • Cardiac surgery within the past 3 months prior to start the wash-out period
  • Stroke within the past 6 months prior to start the wash-out period
  • Renal insufficiency defined as creatininaemia > 2mg/dl
  • Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post renal transplant
  • Liver insufficiency, defined as bilirubinaemia > 2mg/dl and AST (aspartate aminotransferase) or ALT (alanine-aminotransferase) > twice the upper normal range
  • Clinically significant metabolic and endocrine disease
  • Autoimmune disease
  • Previous history of angioedema
  • Body mass index > 30kg/m2
  • Arm circumference > 32 cm
  • Any condition that may be likely to compromise the trial (alcohol or drug abuse, disability illness, etc.)
  • Concomitant therapy with antihypertensive drugs non-permitted by protocol, or present use of tricyclic antidepressant, corticosteroids or drugs known to affect blood pressure
  • Investigational drug treatment within the past 30 days before the enrolment or concurrent participation to any other trial
  • Sensitivity, significant adverse reaction or contraindications to the study drugs (telmisartan, enalapril, clonidine TTS)
  • Predictable lack of patient co-operation

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02177461     History of Changes
Other Study ID Numbers: 502.317
First Posted: June 27, 2014    Key Record Dates
Last Update Posted: July 8, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases
Telmisartan
Clonidine
Enalapril
Enalaprilat
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sympatholytics
Autonomic Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors